Finance Watch: NGM Reemerges With $122m During Post-July 4th VC Mega-Round Boom

Explosion Of $100m-Plus Financings In July

Private Company Edition: After its acquisition by an investor earlier this year, NGM Bio has raised a $122m series A round, adding to a recent surge in large venture capital financings. Also, Vanqua Bio disclosed $45m in new funding and Renalys completed a $38.4m series A.

Finance Watch Private Company
• Source: Shutterstock

NGM Biopharmaceuticals, Inc. added its name to a long and growing list of biopharmaceutical companies raising $100m-plus venture capital mega-rounds with a $122m series A round announced on 17 July. It is NGM Bio’s first financing since February, when it announced that its largest shareholder, The Column Group (TCG), would acquire the then-public company and take it private.

Post-July 4th VC Mega Rounds 

Billions of venture capital dollars have surged into biopharma firms during the first few weeks of July, including Flagship Pioneering’s announcement that it has raised $3.6bn for...

Mega-rounds have driven a surge in venture capital fundraising in 2024, with biopharma companies raising $6.53bn in the first quarter and $8.08bn in Q2 – both representing the highest quarterly...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By 

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By 

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Finance Watch: Public Company Fundraising Sank Across The Board In Q1

 
• By 

Public Company Edition: Biomedtracker’s first quarter 2025 financing report shows follow-on offerings, IPOs and PIPEs fell sharply from Q1 of 2024. In recent transactions, Teva sold $2.3bn worth of notes, Regenxbio executed a royalty deal for up to $250m and Aura’s FOPO grossed $75m.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By 

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

More from Business

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By 

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By 

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.